Since this delivery model targets tumor cells and tumor vasculature, the expression of TNFα gene is localized and self‐controlled; thus, once cell death is completed and the tumor is suppressed, TNFα gene expression should stop, consequently, TNFα production ceases once the therapeutic effect is accomplished. The gene discussed is TNF; the disease is neoplasm.